Moffitt Cancer Center and Fulgent Pharma Collaborate to Transform Cancer Treatment

Moffitt Cancer Center, a globally recognized institution for cancer treatment and research, has formed a strategic partnership with Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. This collaboration aims to advance cancer treatment by leveraging Moffitt’s clinical expertise and Fulgent’s innovative nanotherapeutics and genomics platforms. The partnership is designed to speed up the development of personalized cancer therapies, integrating Moffitt's cutting-edge clinical capabilities with Fulgent's groundbreaking technology.

Under the terms of the agreement, Moffitt will offer Fulgent priority access to its clinical resources and expertise. This includes prioritized clinical trial activation, enhanced patient screening, and data sharing. These measures are intended to expedite the delivery of investigational therapies to patients who are in urgent need of new treatments.

Fulgent Pharma has made significant strides in nanotechnology, particularly in enhancing the solubility of paclitaxel, a chemotherapy drug. The transformed version, FID-007, has shown promising results in Phase 1 clinical trials, demonstrating substantial tumor reduction across various cancer types, including breast, head and neck, lung, bile duct, and pancreatic cancers.

The collaboration will also focus on developing next-generation personalized cancer treatments. Moffitt will utilize its extensive scientific and immunological expertise, along with its access to tissue samples and nonclinical research resources. Fulgent, on the other hand, will contribute its proprietary nano-particle-based drug development platform and extensive genetic and genomic testing capabilities.

Ray Yin, Ph.D., President and Chief Scientific Officer of Fulgent Pharma, emphasized the potential impact of the partnership, stating that combining their unique strengths could lead to the creation of new precision oncology therapies tailored to meet the specific needs of each patient. This approach aims to improve future treatment outcomes significantly.

Patrick Hwu, M.D., President and CEO of Moffitt, highlighted that the partnership aligns with Moffitt’s mission to prevent and cure cancer. He expressed optimism about the collaboration's potential to translate scientific discoveries into life-saving treatments for patients.

Ming Hsieh, CEO of Fulgent Genetics, expressed excitement about the collaboration with Moffitt. He believes that combining Moffitt’s clinical and research expertise with Fulgent’s innovative nanotherapeutic platform will lead to significant advancements in personalized cancer treatment options.

Moffitt Cancer Center is committed to its lifesaving mission of preventing and curing cancer. Recognized as one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, Moffitt is known for its scientific excellence, multidisciplinary research, and robust training and education programs. Its nursing staff has also received the highest distinction from the American Nurses Credentialing Center with Magnet® status.

Fulgent Pharma was initially part of Fulgent LLC, founded in 2011 in Temple City, California. The company later split into Fulgent Pharma and Fulgent Genetics in 2016 to better pursue their distinct objectives. In 2022, Fulgent Pharma was acquired by Fulgent Genetics, aligning their efforts in personalized cancer genomics and precision oncology therapeutics. Fulgent Pharma is now entirely focused on developing drug candidates for treating a broad range of cancers, in partnership with institutions like the University of Southern California, Moffitt Cancer Center, and ANP Technologies.